The latest price target for Monte Rosa Therapeutics (NASDAQ:GLUE) was reported by Wells Fargo on December 19, 2024. The analyst firm set a price target for $11.00 expecting GLUE to rise to within 12 months (a possible 69.23% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Monte Rosa Therapeutics (NASDAQ:GLUE) was provided by Wells Fargo, and Monte Rosa Therapeutics downgraded their equal-weight rating.

The last upgrade for Monte Rosa Therapeutics Inc happened on January 3, 2023 when Wells Fargo raised their price target to $19. Wells Fargo previously had an equal-weight for Monte Rosa Therapeutics Inc.

The last downgrade for Monte Rosa Therapeutics Inc happened on December 19, 2024 when Wells Fargo changed their price target from $14 to $11 for Monte Rosa Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monte Rosa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monte Rosa Therapeutics was filed on December 19, 2024 so you should expect the next rating to be made available sometime around December 19, 2025.

While ratings are subjective and will change, the latest Monte Rosa Therapeutics (GLUE) rating was a downgraded with a price target of $14.00 to $11.00. The current price Monte Rosa Therapeutics (GLUE) is trading at is $6.50, which is out of the analyst’s predicted range.